To: Board of Supervisors
From: Anna Roth, Health Services Director
Report Title: Amendment/Extension #23-764-1 with Becton Dickinson and Company
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Health Services Director, or designee, to execute on behalf of the County (1) Amendment 001 to BD Acquisition Agreement with Becton Dickinson and Company, a corporation, effective June 1, 2024, to increase the payment limit by $51,828, from $200,000 to a new payment limit of $251,828, and to extend the termination date from January 16, 2030 to February 13, 2031 and (2) a Purchase Order for the purchase of a diagnostic instrument (BD BACTEC MGIT 960) for Contra Costa Health’s Public Health Laboratory.
FISCAL IMPACT:
Approval of this amendment will result in additional annual expenditures of up to $51,828 and will be funded as budgeted by the department in FYs 2024-31 by 100% Public Health funds. (No rate increase).
BACKGROUND:
This contract meets the needs of Contra Costa Health (CCH) Public Health Laboratory by executing Amendment 001 to the Becton Dickinson (BD) Acquisition Agreement providing mycobacterium detection equipment, consumables, accessories, embedded software, and services to CCH's Public Health Laboratory. Under the Acquisition Agreement, BD provides testing equipment and consumables, including reagents, panels, supplies, and assays. CCH Public Health Laboratory needs to replace the existing BD BACTEC MGIT 960 diagnostic instrument (which is too old to upgrade) for the continued performance of liquid culture for Mycobacterial species, including tuberculosis. The BD BACTEC MGIT 960 diagnostic instrument can perform liquid culture for Mycobacterial species (including tuberculosis (TB)) on patient specimens and is part of the recommended Centers for Disease Control and Prevention (CDC) screening algorithm for TB. This instrument can analyze and read patient culture tubes over a prolonged incubation. Additionally, this equipment can test TB drug-susceptibility in MGIT culture to determine which TB treatment regimens may or may not be successful for a particular infection. All testing complies with the CDC Clinical Improvement Amendments of 1988 regulations.
A summary of service contact deliverables includes the number of specimens submitted for Mycobacterial culture screening and several tuberculosis specimens that underwent phenotypic drug-susceptibility testing.
On January 17, 2023, the Board of Supervisors approved Contract #23-764 with Becton Dickinson and Company, in an amount not to exceed $200,000, for reagent supplies, software, and maintenance services no equipment purchased) to Contra Costa Health's Public Health Laboratory, for the period from January 17, 2023, through January 16, 2030.
Under Amendment 001 to BD Acquisition Agreement (County Contract #23-764), the parties will execute (1) an amendment to replace the existing equipment (BD BACTEC MGIT 960 S/N MG0269) covered under the agreement and (2) a purchase order to procure the replacement equipment (capital asset).
Approval of Contract Amendment Agreement #23-764-1 will allow the contractor to provide additional mycobacterium detection equipment, consumables, accessories, embedded software, and services to CCH's Public Health Laboratory through February 13, 2031.
CONSEQUENCE OF NEGATIVE ACTION:
If this amendment is not approved the outdated equipment for which parts are unavailable will not be replaced. It will eventually fail, causing patients to visit testing venues outside CCH, which may hurt patient care.